Massively parallel reporter assays and mouse transgenic assays provide correlated and complementary information about neuronal enhancer activity

Michael Kosicki, Dianne Laboy Cintrón, Pia Keukeleire, Max Schubach, Nicholas F. Page, Ilias Georgakopoulos-Soares, Jennifer A. Akiyama, Ingrid Plajzer-Frick, Catherine S. Novak, Momoe Kato, Riana D. Hunter, Kianna Maydell, Sarah Barton, Patrick Godfrey, Erik Beckman, Stephan J. Sanders, Martin Kircher, Len A. Pennacchio and Nadav Ahituv ()
Additional contact information
Michael Kosicki: Lawrence Berkeley National Laboratory
Dianne Laboy Cintrón: University of California San Francisco
Pia Keukeleire: University Medical Center Schleswig-Holstein, University of Lübeck
Max Schubach: Berlin Institute of Health at Charité – Universitätsmedizin Berlin
Nicholas F. Page: University of California San Francisco
Ilias Georgakopoulos-Soares: The Pennsylvania State University College of Medicine
Jennifer A. Akiyama: Lawrence Berkeley National Laboratory
Ingrid Plajzer-Frick: Lawrence Berkeley National Laboratory
Catherine S. Novak: Lawrence Berkeley National Laboratory
Momoe Kato: Lawrence Berkeley National Laboratory
Riana D. Hunter: Lawrence Berkeley National Laboratory
Kianna Maydell: Lawrence Berkeley National Laboratory
Sarah Barton: Lawrence Berkeley National Laboratory
Patrick Godfrey: Lawrence Berkeley National Laboratory
Erik Beckman: Lawrence Berkeley National Laboratory
Stephan J. Sanders: University of California San Francisco
Martin Kircher: University Medical Center Schleswig-Holstein, University of Lübeck
Len A. Pennacchio: Lawrence Berkeley National Laboratory
Nadav Ahituv: University of California San Francisco

Nature Communications, 2025, vol. 16, issue 1, 1-13

Abstract: Abstract High-throughput massively parallel reporter assays (MPRAs) and phenotype-rich in vivo transgenic mouse assays are two potentially complementary ways to study the impact of noncoding variants associated with psychiatric diseases. Here, we investigate the utility of combining these assays. Specifically, we carry out an MPRA in induced human neurons on over 50,000 sequences derived from fetal neuronal ATAC-seq datasets and enhancers validated in mouse assays. We also test the impact of over 20,000 variants, including synthetic mutations and 167 common variants associated with psychiatric disorders. We find a strong and specific correlation between MPRA and mouse neuronal enhancer activity. Four out of five tested variants with significant MPRA effects affected neuronal enhancer activity in mouse embryos. Mouse assays also reveal pleiotropic variant effects that could not be observed in MPRA. Our work provides a catalog of functional neuronal enhancers and variant effects and highlights the effectiveness of combining MPRAs and mouse transgenic assays.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-60064-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60064-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-60064-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().